Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06531863 · ClinicalTrials.gov registry record · Early Phase 1
Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance
A Early Phase 1 study of Mood Disturbance, sponsored by Auburn University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT06531863 is a Early Phase 1 study of Mood Disturbance that is actively recruiting participants, run by Auburn University. The registered enrollment target is 64 participants, above the 45-participant average among 3 other Mood Disturbance trials with a reported enrollment target (42% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06531863, a Early Phase 1 study of Mood Disturbance, is actively recruiting participants, sponsored by Auburn University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this randomized placebo controlled trial is to examine mood disturbance and serum brain derived neurotrophic factor (BDNF) in people (age 18-50) with DASS-21 subscale scores \>9. The main questions it aims to answer are: Does curcumin and EGCG supplementation improve mood disturbance symptomology? Does curcumin and EGCG supplementation increase serum BDNF? Researchers will compare intervention versus placebo. Participants will consume an 8-week supplement of both: * 1,330mg/day curcumin * 350mg/day epigallocatechin gallate (EGCG)
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Curcumin
- DIETARY_SUPPLEMENT Epigallocatechin Gallate
Study Locations (1)
Alabama
- Auburn University School of Kinesiology - Auburn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2025-08-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06531863
The ClinicalTrials.gov registry entry for NCT06531863 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 45-participant average among 3 other Mood Disturbance trials with a reported enrollment target (42% higher). The listed sponsor is Auburn University, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mood Disturbance appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06531863 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT06531863 about?
NCT06531863 is a clinical study titled "Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance". The goal of this randomized placebo controlled trial is to examine mood disturbance and serum brain derived neurotrophic factor (BDNF) in people (age 18-50) with DASS-21 subscale scores \>9. The main questions it aims to answer are: Does curcumin and EGCG supplementation improve mood disturbance sy...
What is the current status of trial NCT06531863?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 64 participants. The study started on 2024-09-30. Estimated completion is 2025-08-01.
What conditions does trial NCT06531863 study?
This clinical trial studies the following conditions: Mood Disturbance.
What interventions are being tested in trial NCT06531863?
The interventions under investigation include: Placebo (OTHER), Curcumin (DIETARY_SUPPLEMENT), Epigallocatechin Gallate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06531863?
This trial is sponsored by Auburn University, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06531863 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mood Disturbance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.